8.48 USD
+0.17
2.05%
At close Dec 20, 4:00 PM EST
After hours
8.48
+0.00
0.00%
1 day
2.05%
5 days
-5.36%
1 month
-10.36%
3 months
-19.01%
6 months
7.89%
Year to date
49.56%
1 year
45.96%
5 years
-88.05%
10 years
-71.78%
 

About: Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Employees: 834

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $2.7M | Put options by funds: $1.36M

8% more capital invested

Capital invested by funds: $182M [Q2] → $196M (+$14.9M) [Q3]

2% more funds holding

Funds holding: 130 [Q2] → 132 (+2) [Q3]

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 39

9.33% less ownership

Funds ownership: 94.78% [Q2] → 85.45% (-9.33%) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for INGN.

Financial journalist opinion

Based on 3 articles about INGN published over the past 30 days

Neutral
Zacks Investment Research
1 week ago
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Neutral
Zacks Investment Research
1 week ago
5 Medical Device Stocks That Survived the 2024 Market Volatility
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
5 Medical Device Stocks That Survived the 2024 Market Volatility
Positive
Zacks Investment Research
3 weeks ago
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Positive
Zacks Investment Research
1 month ago
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Neutral
Seeking Alpha
1 month ago
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript
Call Start: 17:00 January 1, 0000 5:26 PM ET Inogen, Inc. (NASDAQ:INGN ) Q3 2024 Earnings Conference Call November 7, 2024, 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Mike Matson - Needham Operator Welcome to Inogen's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Inogen (INGN) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Inogen (INGN) Reports Q3 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
1 month ago
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.97 per share a year ago.
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 month ago
Inogen Announces Third Quarter 2024 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #COPD--Inogen Announces Third Quarter 2024 Financial Results.
Inogen Announces Third Quarter 2024 Financial Results
Neutral
Business Wire
1 month ago
Inogen to Present at Upcoming Investor Conferences
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #COPD--Inogen to Present at Upcoming Investor Conferences.
Inogen to Present at Upcoming Investor Conferences
Positive
Zacks Investment Research
2 months ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Charts implemented using Lightweight Charts™